Skip to main content

Table 1 Patients characteristics

From: Significance of accurate hilar and intrapulmonary lymph node examination and prognostication in stage IA–IIA non-small cell lung cancer, a retrospective cohort study

Characteristics

N1 LN subgroups

P value

0–2

3–5

6–8

9–11

≥ 12

Overall

n = 181

n = 425

n = 477

n = 414

n = 531

n = 2028

Gender

      

0.289

 Male

103 (56.9)

246 (57.9)

276 (57.9)

245 (59.2)

337 (63.5)

1207 (59.4)

 

 Female

78 (43.1)

179 (42.1)

201 (42.1)

169 (40.8)

194 (36.5)

821 (40.5)

 

Age (year)

60.9 ± 9.6

60.3 ± 9.5

59.5 ± 9.8

59.6 ± 9.3

59.8 ± 9.0

59.9 ± 9.4

0.460

Tumor size (cm)

2.4 ± 1.0

2.5 ± 1.0

2.5 ± 1.0

2.6 ± 1.0

2.6 ± 1.0

2.5 ± 1.0

0.027

Smoking history

      

0.008

 No

115 (63.5)

238 (56.0)

268 (56.2)

224 (54.1)

259 (48.8)

1104 (54.4)

 

 Yes or ever

66 (36.5)

187 (44.0)

209 (43.8)

190 (45.9)

272 (51.2)

924 (45.6)

 

8th TNM stage

      

0.537

 IA

86 (47.5)

222 (52.2)

240 (50.3)

194 (46.9)

256 (48.2)

998 (49.2)

 

 IB–IIA

95 (52.5)

203 (47.8)

237 (49.7)

220 (53.1)

275 (51.8)

1030 (50.8)

 

Histology

      

0.582

 Adenocarcinoma

145 (80.1)

329 (77.4)

365 (76.5)

312 (75.4)

416 (78.3)

1567 (77.3)

 

 Squamous cell carcinoma

19 (10.5)

66 (15.5)

74 (15.5)

68 (16.4)

83 (15.6)

310 (15.3)

 

 Others

17 (9.4)

30 (7.1)

38 (8.0)

34 (8.2)

32 (6.0)

151 (7.4)

 

Differentiation degree

      

0.054

 Well

26 (14.4)

48 (11.3)

28 (5.9)

38 (9.2)

56 (10.5)

196 (9.7)

 

 Moderate

98 (54.4)

224 (52.8)

275 (57.9)

246 (59.6)

264 (49.7)

1107 (54.7)

 

 Poor

57 (31.2)

153 (35.9)

174 (36.2)

130 (31.2)

211 (39.7)

725 (35.6)

 

Visceral pleural invasion

      

0.605

 Negative

119 (65.7)

306 (72.0)

329 (69.0)

288 (69.6)

375 (70.6)

1417 (69.9)

 

 Positive

62 (34.3)

119 (28.0)

148 (31.0)

126 (30.4)

156 (29.4)

611 (30.1)

 

Vascular invasion

      

0.843

 Negative

168 (92.8)

399 (93.9)

442 (92.7)

391 (94.4)

496 (93.4)

1896 (93.5)

 

 Positive

13 (7.2)

26 (6.1)

35 (7.3)

23 (5.6)

35 (6.6)

132 (6.5)

 

Number of N2 LNs examined

      

< 0.001

 0–2

24 (13.3)

24 (5.6)

29 (6.1)

13 (3.1)

21 (4.0)

111 (5.5)

 

 3–5

29 (16.0)

62 (14.6)

66 (13.8)

54 (13.0)

53 (10.0)

264 (13.0)

 

 6–8

40 (22.1)

79 (18.6)

83 (17.4)

68 (16.4)

78 (14.7)

348 (17.2)

 

 9–11

25 (13.8)

56 (13.2)

83 (17.4)

60 (14.5)

76 (14.3)

300 (14.8)

 

 12–14

20 (11.0)

72 (16.9)

69 (14.5)

65 (15.7)

72 (13.6)

298 (14.7)

 

 ≥ 15

43 (23.8)

132 (31.1)

147 (30.8)

154 (37.2)

231 (43.5)

707 (34.9)

 

Adjuvant chemotherapy

      

0.582

 No

160 (88.4)

363 (85.4)

413 (86.6)

368 (88.9)

458 (48.2)

1762 (86.9)

 

 Yes or ever

21 (11.6)

62 (14.6)

64 (13.4)

46 (11.1)

73 (13.7)

266 (13.1)

 

Thoracotomy or VATS

      

0.176

 Thoracotomy

68 (37.6)

193 (45.4)

230 (48.2)

194 (46.9)

242 (45.6)

927 (45.7)

 

 VATS

113 (62.4)

232 (54.6)

247 (51.8)

220 (53.1)

289 (54.4)

1101 (54.3)